The relative binding affinities to human aldose reductase (ALR2) of three new 7-hydroxy-2-benzyl-4H-1-benzopyran-4-one inhibitors were predicted by free energy perturbation (FEP) simulations. Molecular substitutions were specifically designed to investigate the role of hydrogen bonding at the active site of ALR2. Starting from the lead inhibitor 7-hydroxy-2-(4'-hydroxy-benzyl)-4H-1-benzopyran-4-one, the 4'-hydroxyl was mutated to methyl and to trifluoromethyl, and an hydroxyl at position 8 was additionally introduced. Once synthesized and tested as inhibitors of ALR2, the compounds displayed variations of K-i that were in qualitative to quantitative agreement with the calculated relative free energies of binding. The results, discussed in terms of balance between free energies of solvation and free energies of binding to ALR2, elucidate the importance of hydrogen bonding with Thr113 and with Trp111 and cofactor, and provide a rationale to the observed differences in binding affinities. (C) 2002 Elsevier Science Ltd. All rights reserved.
Attenzione! Scheda prodotto non ancora validata dall'Ateneo
|Data di pubblicazione:||2002|
|Titolo:||Binding of 1-benzopyran-4-one derivatives to aldose reductase: A free energy perturbation study|
|Autori:||G. Rastelli; L. Costantino; MC Gamberini; A. Del Corso; U. Mura; JM Petrash; AM Ferrari; S. Pacchioni|
|Autori interni:||RASTELLI, Giulio |
GAMBERINI, Maria Cristina
|Digital Object Identifier (DOI):||10.1016/S0968-0896(01)00408-4|
|Rivista:||BIOORGANIC & MEDICINAL CHEMISTRY|
|Appare nelle tipologie:|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris